AdapCS Canada

AdapCS is a Toronto-based biotechnology company that developed a proprietary platform for the targeted delivery of nucleic acid therapeutics. The company's technology, known as 'Adaptive Cell-Specific' delivery, aims to improve the precision of mRNA and other genetic medicines by ensuring they reach specific tissues and cells while minimizing off-target effects. Founded by Dr. Shana Kelley, a renowned researcher in translational medicine and bio-engineering, AdapCS was acquired by Moderna in February 2023. This acquisition was intended to integrate AdapCS's delivery innovations into Moderna's broader mRNA platform to enhance their therapeutic pipeline. The technology is designed to overcome significant challenges in systemic delivery, particularly for non-liver applications.